{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:50:07Z","timestamp":1776991807025,"version":"3.51.4"},"reference-count":31,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Tangshan Youth Science and Technology Project","award":["20211801"],"award-info":[{"award-number":["20211801"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Acute myocardial infarction (AMI) significantly contributes to the progression of heart failure (HF). Standard treatment for HF has long been angiotensin-converting enzyme inhibitors (ACEIs), targeting the renin-angiotensin-aldosterone system (RAAS). Recent developments in HF management introduced sacubitril\/valsartan (S\/V), a novel angiotensin receptor-neprilysin inhibitor (ARNI), showing promising results in global trials. This study aimed to assess the efficacy of early S\/V application compared to angiotensin-converting enzyme inhibitors (ACEIs) in reducing NT-proBNP levels and improving clinical outcomes, specifically focusing on dyspnea symptomatology, in Chinese patients with AMI complicated by HF.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This single-center, mixed methods study was conducted at Tangshan Gongren Hospital from January to December 2021, including 88 patients diagnosed with AMI and HF. Patients were divided into two groups: 31 received S\/V, while 57 were treated with ACEIs. Data collection encompassed baseline demographic, clinical, and biochemical variables, NT-proBNP levels, blood pressure measurements, and dyspnea symptom severity. Follow-up assessments were conducted 1 year post-discharge to evaluate NT-proBNP levels, and symptom progression. Statistical analyses, including t-tests, Wilcoxon rank-sum tests, and chi-square tests, were performed to compare outcomes between the two groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>At baseline, no significant differences were observed between the two groups in terms of demographic, lifestyle, and medical history. Although patients in the S\/V group presented with more severe baseline renal impairment and cardiac dysfunction, there was no significant difference in NT-proBNP levels from admission to discharge. 1-year follow-up showed a trend towards reduced NT-proBNP levels in the S\/V group, though this difference did not reach statistical significance. All patients in both groups reported improvements in dyspnea at discharge and at follow-up, with no significant inter-group difference. Notably, the S\/V group demonstrated a more significant reduction in both systolic and diastolic blood pressure from admission to discharge compared to the ACEIs group.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This study found that S\/V had similar effects to ACEIs in reducing NT-proBNP levels among Chinese patients with AMI complicated by HF, though S\/V was associated with greater reductions in blood pressure. These findings suggest that while S\/V may offer additional benefits in blood pressure management, its impact on cardiac biomarkers in acute settings may not significantly differ from ACEIs. Given the study\u2019s limitations, including its single-center design, small sample size, and baseline differences. Further multi-center, randomized controlled trials are warranted to validate these findings and explore tailored treatment strategies for AMI patients with concurrent HF.<\/jats:p>\n<\/jats:sec>","DOI":"10.7717\/peerj.18873","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T08:15:38Z","timestamp":1739261738000},"page":"e18873","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of sacubitril\/valsartan on improving clinical symptoms in patients with acute myocardial infarction complicated with heart failure: a retrospective study"],"prefix":"10.7717","volume":"13","author":[{"given":"Guiping","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Cardiology, Tangshan Gongren Hospital, Tangshan, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruolin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Natural and Applied Science, Duke Kunshan University, Kunshan, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuyang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tangshan Gongren Hospital, Tangshan, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuping","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tangshan Gongren Hospital, Tangshan, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tangshan Gongren Hospital, Tangshan, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tangshan Gongren Hospital, Tangshan, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suya","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tangshan Gongren Hospital, Tangshan, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juanjuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tangshan Gongren Hospital, Tangshan, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaokun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tangshan Gongren Hospital, Tangshan, Hebei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4443","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"issue":"72","key":"10.7717\/peerj.18873\/ref-1","doi-asserted-by":"publisher","first-page":"e8295054","DOI":"10.1155\/2019\/8295054","article-title":"Burden of coronary artery disease and peripheral artery disease: a literature review","volume":"2019","author":"Bauersachs","year":"2019","journal-title":"Cardiovascular Therapeutics"},{"key":"10.7717\/peerj.18873\/ref-2","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3760\/cma.j.cn112148-20201009-00796","article-title":"Chinese guideline on the primary prevention of cardiovascular diseases","volume":"48","author":"Cardiovascular Disease Prevention and Rehabilitation Committee of Chinese Association of Rehabilitation Medicine","year":"2020","journal-title":"Zh\u014dnghu\u00e1 x\u012bnxu\u00e8gu\u0103nb\u00ecng z\u00e1zh\u00ec"},{"issue":"5","key":"10.7717\/peerj.18873\/ref-3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jchf.2020.03.002","article-title":"Effects of Sacubitril\/Valsartan on N-terminal pro-B-Type natriuretic peptide in heart failure with preserved ejection fraction","volume":"8","author":"Cunningham","year":"2020","journal-title":"JACC: Heart Failure"},{"issue":"7","key":"10.7717\/peerj.18873\/ref-4","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1093\/eurheartj\/ehz665","article-title":"Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme","volume":"41","author":"Danchin","year":"2020","journal-title":"European Heart Journal"},{"issue":"3","key":"10.7717\/peerj.18873\/ref-5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5339\/gcsp.2013.34","article-title":"RAAS inhibition and mortality in hypertension","volume":"2013","author":"Ferrari","year":"2013","journal-title":"Global Cardiology Science & Practice"},{"issue":"1","key":"10.7717\/peerj.18873\/ref-6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/ijms21010206","article-title":"Tonic activation of extrasynaptic NMDA receptors decreases intrinsic excitability and promotes bistability in a model of neuronal activity","volume":"21","author":"Gall","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.7717\/peerj.18873\/ref-7","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.3389\/fphar.2023.1237210","article-title":"The efficacy and safety of sacubitril\/valsartan compared with ACEI\/ARB in the treatment of heart failure following acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Gao","year":"2023","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"10.7717\/peerj.18873\/ref-8","doi-asserted-by":"publisher","first-page":"e002460","DOI":"10.1161\/CIRCHEARTFAILURE.115.002460","article-title":"Mortality associated with heart failure after myocardial infarction: a contemporary community perspective","volume":"9","author":"Gerber","year":"2016","journal-title":"Circulation. Heart Failure"},{"issue":"6","key":"10.7717\/peerj.18873\/ref-9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s40292-023-00606-0","article-title":"Sacubitril\/Valsartan in heart failure with hypertension patients: real-world experiences on different ages, drug doses, and renal functions","volume":"30","author":"Guan","year":"2023","journal-title":"High Blood Pressure & Cardiovascular Prevention: The Official Journal of the Italian Society of Hypertension"},{"key":"10.7717\/peerj.18873\/ref-10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3760\/cma.j.issn.0253-3758.2018.10.004","article-title":"Chinese guidelines for the diagnosis and treatment of heart failure 2018","volume":"46","author":"Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Chinese Heart Failure Association of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiology","year":"2018","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"8","key":"10.7717\/peerj.18873\/ref-11","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.amjcard.2004.12.032","article-title":"The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study","volume":"95","author":"Januzzi","year":"2005","journal-title":"The American Journal of Cardiology"},{"issue":"3","key":"10.7717\/peerj.18873\/ref-12","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/eurheartj\/ehi631","article-title":"NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the international collaborative of NT-proBNP study","volume":"27","author":"Januzzi","year":"2006","journal-title":"European Heart Journal"},{"issue":"4","key":"10.7717\/peerj.18873\/ref-13","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ahj.2011.08.002","article-title":"Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial","volume":"162","author":"Kelly","year":"2011","journal-title":"American Heart Journal"},{"issue":"6","key":"10.7717\/peerj.18873\/ref-14","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3892\/etm.2022.11333","article-title":"Protective effect of sacubitril\/valsartan in patients with acute myocardial infarction: a meta-analysis","volume":"23","author":"Liu","year":"2022","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"12","key":"10.7717\/peerj.18873\/ref-15","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/eurheartj\/ehs262","article-title":"Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics","volume":"34","author":"Mangiafico","year":"2013","journal-title":"European Heart Journal"},{"issue":"1","key":"10.7717\/peerj.18873\/ref-16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"7","author":"Mann","year":"2022","journal-title":"JAMA Cardiology"},{"issue":"11","key":"10.7717\/peerj.18873\/ref-17","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-Neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.7717\/peerj.18873\/ref-18","article-title":"Acute myocardial infarction","volume-title":"StatPearls [Internet]","author":"Mechanic","year":"2023"},{"issue":"1","key":"10.7717\/peerj.18873\/ref-19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40885-019-0132-x","article-title":"Blood pressure and heart failure","volume":"26","author":"Oh","year":"2020","journal-title":"Clinical Hypertension"},{"issue":"20","key":"10.7717\/peerj.18873\/ref-20","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor-Neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.7717\/peerj.18873\/ref-21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure","volume":"113","author":"Roger","year":"2013","journal-title":"Circulation Research"},{"key":"10.7717\/peerj.18873\/ref-22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12872-023-03231-w","article-title":"The global prevalence of myocardial infarction: a systematic review and meta-analysis","volume":"23","author":"Salari","year":"2023","journal-title":"BMC Cardiovascular Disorders"},{"issue":"35","key":"10.7717\/peerj.18873\/ref-23","doi-asserted-by":"publisher","first-page":"106303","DOI":"10.1016\/j.phrs.2022.106303","article-title":"Angiotensin receptor\/Neprilysin inhibitor effects in CRTd non-responders: from epigenetic to clinical beside","volume":"182","author":"Sardu","year":"2022","journal-title":"Pharmacological Research"},{"issue":"2","key":"10.7717\/peerj.18873\/ref-24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10741-018-9757-1","article-title":"Practical guidance on the use of sacubitril\/valsartan for heart failure","volume":"24","author":"Sauer","year":"2019","journal-title":"Heart Failure Reviews"},{"issue":"9851","key":"10.7717\/peerj.18873\/ref-25","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"The Lancet"},{"issue":"1","key":"10.7717\/peerj.18873\/ref-26","doi-asserted-by":"publisher","first-page":"e002667","DOI":"10.1161\/JAHA.115.002667","article-title":"Heart failure complicating acute myocardial infarction; burden and timing of occurrence: a nation-wide analysis including 86 771 patients from the cardiovascular disease in Norway (CVDNOR) project","volume":"5","author":"Sulo","year":"2016","journal-title":"Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease"},{"issue":"6","key":"10.7717\/peerj.18873\/ref-27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.7717\/peerj.18873\/ref-28","doi-asserted-by":"publisher","first-page":"e013296","DOI":"10.1161\/JAHA.119.013296","article-title":"ST-segment-elevation myocardial infarction (STEMI) patients without standard modifiable cardiovascular risk factors-how common are they, and what are their outcomes?","volume":"8","author":"Vernon","year":"2019","journal-title":"Journal of the American Heart Association"},{"key":"10.7717\/peerj.18873\/ref-29","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/ehf2.12584","article-title":"Cardiomyocyte-derived exosomal microRNA-92a mediates post-ischemic myofibroblast activation both in vitro and ex vivo","volume":"7","author":"Wang","year":"2020","journal-title":"ESC Heart Failure"},{"key":"10.7717\/peerj.18873\/ref-30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ijcard.2015.03.116","article-title":"Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis","volume":"186","author":"Wang","year":"2015","journal-title":"International Journal of Cardiology"},{"issue":"10","key":"10.7717\/peerj.18873\/ref-31","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/clc.23717","article-title":"Efficacy and safety of early initiation of Sacubitril\/Valsartan in patients after acute myocardial infarction: a meta-analysis","volume":"44","author":"Zhao","year":"2021","journal-title":"Clinical Cardiology"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/18873.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/18873.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/18873.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/18873.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T08:15:48Z","timestamp":1739261748000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/18873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":31,"alternative-id":["10.7717\/peerj.18873"],"URL":"https:\/\/doi.org\/10.7717\/peerj.18873","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"article-number":"e18873"}}